Compare MDBH & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | AYTU |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3M | 27.4M |
| IPO Year | 2022 | 2015 |
| Metric | MDBH | AYTU |
|---|---|---|
| Price | $2.95 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 2.0K | ★ 31.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | $4.06 | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $2.45 | $1.65 |
| 52 Week High | $4.80 | $3.07 |
| Indicator | MDBH | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 49.18 |
| Support Level | $2.80 | $2.08 |
| Resistance Level | $3.23 | $2.32 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 19.72 | 29.54 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.